

Form PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY DOCKET NO.: EMU144CIP	SERIAL NO.: 10/056,913
MATERIAL INFORMATION STATEMENT (Use several sheets if necessary)		APPLICANT: Harish C. Joshi, et al.	
		FILING DATE: January 25, 2002	GROUP: 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,376,516 B1	04/23/02	Joshi, et al.	514	328	RECEIVED JUL 31 2002 TECH CENTER 1600/2900
	5,213,808	05/25/93	Bar-Shalom, et al.	424	173	
	5,100,669	03/31/92	Hyon, et al.	424	426	
	4,994,281	02/19/91	Muranishi, et al.	424	427	
	4,816,462	03/28/89	Nowicky	514	274	
	3,108,106	10/22/63	Maillard	260	283	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	3-42279	06/26/91	Japan			X
	63-183540	06/26/91	Japan			X
	53-41415	04/14/78	Japan			X
	WO 83/00486	02/17/83	PCT			X
	1191837	08/13/85	Canada			X
	2110533A	07/13/82	United Kingdom			

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	Al-Yuhya and Hassan, in K.Florey (Ed.), "Noscapine," <i>Analytical Profiles of Drug Substances</i> , Vol. 11 Academic Press, pp. 407-461 (1982)
	Battersby, et al., "Concerning The Biosynthesis of Narcotine," <i>Tetrahedron Lett.</i> 11:669-673 (1965)
	Empey, D.W., et al., <i>Eur. J. Clin. Pharmacol.</i> 16, 393-397 (1979).
	Fleishchhacker, et al., <i>Chem. Monthly</i> 120:765-769 (1989);
	Gavrieli, Y. et al., "Identification of Programmed Cell Death in Situ via Specific Labeling of Nuclear DNA Fragmentation," <i>J. Cell Bio.</i> 119:493-501 (1992).
	Gorczyca, W. et al., "Detection of DNA Strand Breaks in Individual Apoptotic Cells by the in Situ Terminal Deoxynucleotidyl Transferase and Nick Translation Assays," <i>Cancer Res.</i> 53:1945-1951 (1993)
EXAMINER:	DATE CONSIDERED: January 2, 2003
EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
















RECEIVED

JUL 31 2002

Page 2 of 4

TECH CENTER 1600/2900

Form PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY DOCKET NO.: EMU144CIP	SERIAL NO.: 10/056,913
MATERIAL INFORMATION STATEMENT (Use several sheets if necessary)		APPLICANT: Harish C. Joshi, et al.	
		FILING DATE: January 25, 2002	GROUP: 1614

	Joshi, et al., "γ-Tubulin is a centrosomal protein required for cell cycle-dependent microtubule nucleation," <i>Nature</i> , 356:80-83 (1992)
	Ke, et al., "Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses," <i>Cancer Immunol. Immunotherapy</i> , (2000)
	Ke, et al., "Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells," <i>Proc. Natl. Acad. Sci. USA</i> , 95:1601-1606 (1998)
	Kerekcs and Bogner, "Synthese des Gnoscopins (DL-Narcotin)," <i>J. Prakt. Chem.</i> 313:923-928 (1971)
	Landen, et al., "Noscapine Alters Microtubule Dynamics in Living Cells and Inhibits the Progression of Melanoma," pp. 1-5, figs. 1-4 (unpublished manuscript on file with Emory University School of Medicine, 2001))
	Landen, et al., "The Microtubule Interacting Agent Noscapine for the Treatment of Glioblastoma in Immunodeficient Mice," <i>Cancer Research Abstract Book</i> and on AACR website (2000)
	Landen, et al., "Treatment of Murine Melanoma by Noscapine, a Tubulin Interacting Agent," <i>Cancer Research Abstract Book</i> and on AACR website (2001)
	Molnar, et al., "In vitro antiproliferative effects of tricyclic psychopharmaceutical agents and synergism with some resistance modifiers," <i>Anticancer Res.</i> , 12(1):273-280 (1992)
	Moore, M.W., et al., "Introduction of Soluble Protein into the Class I Pathway of Antigen Processing and Presentation," <i>Cell</i> 54:777-785 (1988)
	Perkin and Robinson, "Synthesis and Resolution of Gnoscopine," <i>J. Chem. Soc. [London]</i> , 99:775-798 (1911)
	Perry, Michael, <i>Chemotherapy Source Book</i>, (Williams & Wilkins 2d ed., 1997)
EXAMINER: 	DATE CONSIDERED:  January 2, 2003
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



RECEIVED

JUL 31 2002

TECH CENTER 1600/2900

Page 3 of 4

Form PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY DOCKET NO. EMU144CIP	SERIAL NO. 10/056,913
MATERIAL INFORMATION STATEMENT (Use several sheets if necessary)		APPLICANT: Harish C. Joshi, et al.	
		FILING DATE: January 25, 2002	GROUP: 1614

	Peyrot, V. et al., "Mechanism of Binding of the New Antimitotic Drug MDL 27048 to the Colchicine Site of Tubulin: Equilibrium Studies," <i>Biochemistry</i> 31:11125-11132 (1992)
	Pinko, C., "Single-chain Recombinant Human Cytomegalovirus Protease," <i>J. Biol. Chem.</i> , 270(40):23634-23640 (1995)
	Powers, J.C., et al., "Reaction of Porcine Pancreatic Elastase with 7-Substituted 3-Alkoxy-4-chloroisocoumarins: Design of Potent Inhibitors Using the Crystal Structure of the Complex Formed with 4-Chloro-3-ethoxy-7-guanidinoisocoumarin," <i>Biochemistry</i> 29:3108-3118 (1990)
	Prior, S.; "Borane adducts of narcotine, hydrastine and their reduction products," <i>Arch. Pharm.</i> 316(9):737-746 (1983) (chemical Abstracts Vol. 99, 176115z (1983))
	Sam, J. et al., "Preparation and Properties of Some Relatives of Noscapine," <i>J. Pharm. Sci.</i> 57:-1755-1759 (1968)
	Shono, T. et al., "New Electroreductive Synthesis of Phthalide Alkaloids," <i>Tetrahedron Lett.</i> , 21:1351-1354 (1980)
	Sin, "Medicinal Plant Alkaloids," 2nd Ed. Un. Toronto Press, page 70 (1970)
	Uchegbu, "Science in Pharmacy Parenteral drug delivery," <i>Pharmaceutical Journal</i> , 263(7061):355-358 (1999) and www.pharmj.com/Editorial/19990904/education/parenteral2.html
	Uchegbu, et al., "Science in Pharmacy, Parenteral drug delivery: 1," <i>Pharmaceutical Journal</i> , 263(7060):309-318 (1999)
	Uhrin, et al., <i>Collect. Czech. Chem. Commun.</i> 54:498 (1989)
	Walton, M.I. et. al., "Constitutive Expression of Human <i>Bcl-2</i> Modulates Nitrogen Mustard and Camptothecin Induced Apoptosis," <i>Cancer. Res.</i> 53:1853-1861 (1993)
EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	














RECEIVED

JUL 31 2002

TECH CENTER 1600/2900 Page 4 of 4

Form PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY DOCKET NO.: EMU144CIP	SERIAL NO.: 10/056,913
MATERIAL INFORMATION STATEMENT (Use several sheets if necessary)		APPLICANT: Harish C. Joshi, et al.	
		FILING DATE: January 25, 2002	GROUP: 1614

	Witt, et al., "Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability," <i>Peptides</i> , 22:2329-2343 (2001)
	"Noscapine," Chemical Abstracts, page 1063 No. 6638
	"Offering Hope in the Treatment of Brain Cancer," http://www.gliadel.com (01/16/02) (16 pages)
	"The Brain Infusion Kit and Brain Infusion Kit II," http://www.alzet.com/products/products-sec05.html (01/16/02) (2 pages))
	"In Vivo Pharmacology," http://www.alzet.com/products/products-sec03.html (01/16/02) (2 pages)
	"A General Description," http://www.alzet.com/products/products-sec01.html (01/16/02) (1 page)
	"DUROS®," http://www.durect.com/wt/durect/page-name/duros (01/22/02) (2 pages)
	"BBBD THERAPY," http://www.ohsu.edu/hosp-bbb/bbbdtherapy.html (01/22/02) 3 pages)
	"The Microtubule Interacting Agent, Noscapine, for the Treatment of Glioblastoma and Melanoma," New Data, Department of Cell Biology, Emory University, Joshi Laboratory (undated)
EXAMINER: 	DATE CONSIDERED: 
EXAMINER: Initial in reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	